Calcium/calcimimetic via calcium-sensing receptor ameliorates cholera toxin-induced secretory diarrhea in mice

Abstract

BACKGROUND

Enterotoxins produce diarrhea through direct epithelial action and indirectly by activating the enteric nervous system. Calcium-sensing receptor (CaSR) inhibits both actions. The latter has been well documented in vitro but not in vivo. The hypothesis to be tested was that activating CaSR inhibits diarrhea in vivo.

AIM

To determine whether CaSR agonists ameliorate secretory diarrhea evoked by cholera toxin (CTX) in mice.

METHODS

CTX was given orally to C57BL/6 mice to induce diarrhea. Calcium and calcimimetic R568 were used to activate CaSR. To maximize their local intestinal actions, calcium was administered luminally via oral rehydration solution (ORS), whereas R568 was applied serosally using an intraperitoneal route. To verify that their actions resulted from the intestine, effects were also examined on Cre-lox intestine-specific CaSR knockouts. Diarrhea outcome was measured biochemically by monitoring changes in fecal Cl^- or clinically by assessing stool consistency and weight loss.

RESULTS

CTX induced secretory diarrhea, as evidenced by increases in fecal Cl^-, stool consistency, and weight loss following CTX exposure, but did not alter CaSR, neither in content nor in function. Accordingly, calcium and R568 were each able to ameliorate diarrhea when applied to diseased intestines. Intestinal CaSR involvement is suggested by gene knockout experiments where the anti-diarrheal actions of R568 were lost in intestinal epithelial CaSR knockouts (^villinCre/Casr^flox/flox) and neuronal CaSR knockouts (^nestinCre/Casr^flox/flox).

CONCLUSION

Treatment of acute secretory diarrheas remains a global challenge. Despite advances in diarrhea research, few have been made in the realm of diarrhea therapeutics. ORS therapy has remained the standard of care, although it does not halt the losses of intestinal fluid and ions caused by pathogens. There is no cost-effective therapeutic for diarrhea. This and other studies suggest that adding calcium to ORS or using calcimimetics to activate intestinal CaSR might represent a novel approach for treating secretory diarrheal diseases.

Core Tip: Treatment of diarrhea remains a global challenge. Enterotoxins induce diarrhea through direct epithelial action and indirectly by activating the enteric nervous system. Using in vitro models in isolated tissues, we have previously shown that calcium-sensing receptor (CaSR) inhibits both actions. In the present study, we use a mouse model of secretory diarrhea in conjunction with a tissue-specific knockout approach and demonstrate that calcium or calcimimetic via CaSR ameliorates cholera toxin-induced secretory diarrhea in vivo. This study suggests that adding calcium to oral rehydration solution or using calcimimetic to activate intestinal CaSR might represent a new approach for treating secretory diarrheal diseases.

INTRODUCTION

Acute infectious diarrhea remains among the top causes of morbidity and deaths in children throughout the world[1,2]. According to the United Nations Children’s Fund/World Health Organization[3], approximately 9 million children (about half the population of New York) under 5 years died in 2008. 40% of these deaths were due to two diseases: Pneumonia and diarrhea. Diarrhea remains the second leading cause of death in children younger than 5 years globally, accounting for one in every five child deaths - around 1.5 million a year - more than acquired immune deficiency syndrome, malaria, and measles combined. Importantly, most of the morbidity and mortality is not due to infection but dehydration. Accordingly, reducing the fluid loss from acute diarrhea offers a major opportunity for improving child health globally.

Enterotoxins induce diarrhea through direct epithelial action and indirectly by activating the enteric nervous system (ENS)[4]. For example, cholera induces diarrhea through the generation of cholera toxin (CTX) from V. cholera. CTX binds to the enterocyte, leading to ADP-ribosylation of the G_s α-subunit. This constitutively activates membrane-bound adenylyl cyclase in enterocytes and elevates intracellular cyclic adenosine monophosphate (cAMP). Increased cAMP stimulates protein kinase A and phosphorylation of the cystic fibrosis transmembrane conductance regulator (CFTR) channel, as well as the Na⁺/K⁺/2Cl^- cotransporter (NKCC1), causing secretion of Cl^- and water. Elevated cAMP levels also inhibit Cl^- and water absorption mediated by Cl^-/HCO₃^- exchange and Na⁺/H⁺ exchange[4,5]. In addition to direct epithelial action, CTX elicits neuronal secretory reflexes by binding to mucosal enterochromaffin cells, leading to the production of 5-hydroxytryptamine, activation of ENS and release of neurotransmitters (e.g., vasoactive intestinal peptide and acetylcholine) that stimulate and amplify fluid secretion, leading to dehydration and rapid body weight loss[4,6,7].

Importantly, the extracellular calcium-sensing receptor (CaSR)[8] is present on cells in both pathways[5,9,10] and, when activated in vitro, blocks both diarrhea-causing pathways evoked by CTX and other diarrhea-causing enterotoxins/secretagogues. For example, using a microperfused colonic crypt technique, it has been shown that calcium, calcimimetics or polyamines that activate CaSR can act on intestinal epithelium and reverse CTX/forskolin-induced fluid secretion using a signal transduction pathway that promotes cyclic nucleotide destruction[11-13]. Using Ussing chambers, it has been shown that the effects of CTX/forskolin and CaSR agonists on electrolyte secretion by the intestine can also be attributed to opposing actions of enterotoxins/secretagogues and CaSR on ENS activity[14,15]. These results suggest that targeting intestinal CaSR might represent a previously undescribed novel approach for treating secretory diarrheal diseases[5,9,10,16-18]. However, all of the experiments that suggest CaSR modulates dual-pathway secretion by the intestine have been performed in vitro in isolated tissues. Neither the functionality of the CaSR receptors in vivo nor the anti-diarrheal potential of CaSR agonists in live animals have been documented, although the latter is necessary before clinical trials in humans are performed.

In this study, we tested the hypothesis that calcium/calcimimetic via CaSR ameliorates secretory diarrhea in vivo in mice. A CTX mouse model of secretory diarrhea was employed and the effects of CaSR agonists on biochemical (i.e., changes in fecal Cl^-) and clinical outcomes (i.e., changes in stool consistency and body weight loss) of secretory diarrheal disease were assessed. We selected the CTX mouse model because we had employed it as a model in previous in vitro studies. In addition, it has been widely used to provide proof of concept of whether an anti-diarrheal agent is therapeutic or not[19-22]. In addition to testing calcium, we also examined the effects of the calcimimetic R568, a pharmacological allosteric CaSR agonist[23]. To maximize their local intestinal actions, we delivered agonists as follows: Calcium was administered orally by adding it to oral rehydration solution (ORS) and R568 was applied serosally using an intraperitoneal route, as previously described[15]. To verify that their actions resulted from intestinal tissues and not a non-specific off-target action, the effects were also measured on intestine-specific CaSR knockouts. We show for the first time that targeting intestinal CaSR with calcium or calcimimetic is efficacious in reducing CTX-evoked secretory diarrhea in vivo in live animals and that this occurs through receptor-mediated reduction of both the neurally and non-neuronally mediated secretory responses. A portion of this work was presented in an abstract in the Global Health Forum of 5^th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition[24].

MATERIALS AND METHODS

Animals

Experiments were performed using male/female C57BL/6 mice (wild type and Casr mutants). Mice lacking CaSR expression in intestinal epithelial cells (^villinCre/Casr^flox/flox mice) and mice lacking CaSR expression in intestinal neurons (^nestinCre/Casr^flox/flox mice) and their wild type littermates were bred and maintained in-house at the University of Florida Communicore Animal Facility. Mutant mice were generated as previously described[25,26]. Briefly, CaSR flox/flox mice were bred with transgenic mice expressing Cre recombinase under the control of the Villin 1 or Nestin promoter and genotyped prior to all experiments after approximately 20-30 generations. Mice were used at 5-10 wk of age and weight of 17-23 g in accordance with the Animal Welfare Act and the Public Health Policy on Humane Care. Animals were fed and maintained on regular chow (Harlan) with free access to water before the experiment. To maximally protect animal welfare, we used numbers of animals in each experiment group as minimal and small as scientifically or statistically allowed. Thus, depending on variation of the data obtained and/or availability of the animals tested, 5-11 animals were employed, although 2-3 animals were used in some dose-dependence studies. This was because these were the minimal numbers required for statistical significance using one-way ANOVA and P < 0.05 as determined in a pilot experiment. To minimize the effects of subjective bias in allocating animals, we treated controls, interventions, wild type, and mutants in the same manner on the same days by the same investigators. The animal protocols were designed to minimize pain or discomfort to the animals. After completion of the experiment, animals were sacrificed with standard CO₂ inhalation and by cervical dislocation. The use of animals as well as the protocols for CTX treatment and colon tissue isolation was approved by the Institutional Animal Care and Use Committee (IACUC# 201807567) at the University of Florida.

CTX mouse model of secretory diarrhea

Two protocols were used to induce diarrhea: Protocol 1 is long and was used to compare the effects of with vs without oral calcium, a poorly absorbed mineral agonist of CaSR[27-29]; whereas protocol 2 is short and was used to compare the effects of with vs without R568, a quickly absorbable small-molecule agonist of CaSR[30].

Protocol 1: Animals were first fasted overnight for 16 h before they were gavaged intragastrically (i.g.) with 200 μL 7% NaHCO₃ buffer containing 20 μg CTX or vehicle per mouse to induce diarrhea. After CTX gavage, animals were fasted for an additional 90 min before they were allowed access to regular chow to avoid food interference on toxin binding and action. Afterwards, animals were divided into two groups: Group 1 received drinking bottles containing ORS only whereas Group 2 received drinking bottles containing ORS supplemented with 5 mmol/L calcium. This calcium concentration was selected because it is the lowest concentration of calcium that generated maximal CaSR-activation effects[11,12]. Diarrhea was monitored and was either semi-quantitated clinically according to stool consistency [0, normal feces (solid); 1, moist feces (semi-solid); 2, mild diarrhea (loose); and 3, severe diarrhea (watery)[31]] or quantitated biochemically according to fecal Cl^- content. Degree of dehydration was measured by diarrhea-associated body weight loss[32]. In this study, the onset of diarrhea is defined as the appearance of the first diarrheic stool with stool consistency scored one or higher, as described[31].

Protocol 2: Animals were pretreated and treated as in protocol 1 except for the following: (1) Calcimimetic R568 (diluted in 100 μL normal saline) was administered serosally at the time when diarrhea was induced. R568 was administered serosally using an intraperitoneally (i.p.) rather than per os route to minimize the unwanted systemic effects while maximizing the desired local intestinal action as described[15]. Neither anesthesia nor analgesia were used; (2) 1.5 h post CTX treatment, animals were allowed to drink ORS without calcium; and (3) Animals were sacrificed 3.5 h after CTX treatment before watery stool was seen. Pilot studies showed that diarrhea started to occur about 0.5 h post CTX gavage and reached a peak plateau about 1.5 h later[33], but no diarrheic stool was seen until 3.5 h post CTX treatment. Three and half-hours later, animals were killed, fluid accumulated in the intestine was removed and weighed, changes compared, and is expressed as mg/mg intestine.

Fecal Cl^- measurement

Feces were collected in pre-weighed Eppendorf tubes. To avoid variations from freeze-thaw cycle and bacterial overgrowth from storage, all fecal samples were collected, gently processed, and promptly measured as described[34]. In brief, following collection, samples were weighed and diluted appropriately in deionized water so that the Cl^- content in each sample fell within the linear range of the standard curve. Diluted samples were gently but thoroughly homogenized through pipetting before centrifugation at 14000 g for 10 min. Sonication was not used to minimize release of intracellular contents. The resulting supernatants were collected, and Cl^- contents measured with an ion-selective electrode by potentiometric titration (Model LIS-146CLCM-XS system; JENCO Electronics, Ltd, Taipei City, Taiwan). The results were calculated according to the standard curve, and are expressed as mole/L, where 1 L of feces ≈ 1 kg of feces. Previous studies have shown that these methods caused no or minimal variations in fecal Cl^-[34-36].

CaSR western blot

Isolation and preparation of intestinal homogenates and lysates and western blot analysis of CaSR protein were performed as previously described[12] with an affinity-purified mouse monoclonal antibody (5C10, ADD) raised against a 22-amino acid peptide corresponding to amino acid residues 214-235 of human CaSR (Abcam, Cambridge, MA, United States). CaSR protein signals were normalized against heat shock protein 90 (HSP90) as a loading control and are expressed as CaSR/HSP90 protein signal ratios[37].

Chemicals, antibodies, and solutions

CTX was obtained from Sigma (St Louis, MO, United States), and 5 mg/mL stock solutions were prepared in water. R568 was purchased from Tocris Bioscience (Ellisville, MI, United States), and 20 mg/mL stock solutions were prepared in 15% 2-hydroxypropyl-β-cyclodextrin (Research Biochemicals International, Natick, MA, United States). Calcium chloride was from Sigma, and rabbit polyclonal antibody against HSP90 was from Santa Cruz Biotechnology (Dallas, TX, United States). ORS was prepared fresh containing (in mmol/L) 75 Na⁺, 20 K⁺, 65 Cl^-, 10 citrate and 75 glucose with total osmolarity of 245 mOsm/kg H₂O.

Statistical analysis

The statistical methods of this study were reviewed by Dr. Han-Zhi Gao, PhD, member of the Biostatistics Service from the Clinical and Translational Science Institute of the University of Florida. Data from all animals were included in the analysis. Values are given as means ± standard error of the mean. The normality of variables was checked; the data for intestinal fluid accumulations exhibited a skewed distribution and were therefore log transformed. After log transformation, the data became normally distributed. Statistical comparisons between two means were performed by Student’s t-test, whereas comparisons among multiple means were by one-way ANOVA with Tukey’s post hoc tests. Both tests were performed using Microsoft Excel 2016 for Windows or using GraphPad Prism version 6.07 for Windows (GraphPad Software, San Diego, CA, United States). P < 0.05 was considered significant.

RESULTS

Effects of calcimimetic

Our first set of experiments was performed with the calcimimetic R568 used in conjunction with intestinal CaSR-specific knockouts to demonstrate the functionality of intestinal CaSR in vivo and to demonstrate the intestinal specificity of the agent. In these experiments, diarrhea-provoking CTX or vehicle was given i.g. whereas the anti-diarrheal R568 or vehicle was administered i.p. to avoid interference between the two agents. For accurate quantification, diarrhea was induced such that all the secreted fluid was contained inside the intestinal lumen without loss outside of the body. Before they were sacrificed, animals did not exhibit any noticeable adverse effects. Data from all animals were included in the analysis.

CTX induces secretory diarrhea but does not alter CaSR expression in the intestine

In unstimulated vehicle-gavaged wild type mice, intestinal fluid accumulation was 0.20 ± 0.02 mg/mg intestine. Intragastric gavage of CTX caused diarrhea, as evidenced by increased intestinal fluid accumulation in a dose-dependent fashion (Figure 1). At the EC₅₀ of approximately 0.5 mg/kg, the amount of intestinal fluid accumulation was 1.46 ± 0.15 mg/mg intestine, which is about a 7-fold increase in intestinal fluid accumulation compared to non-CTX controls (Table 1).

Figure 1.

Cholera toxin induces diarrhea but does not alter calcium-sensing receptor in the intestine. A: Representative images of fluid accumulation in the intestine; B: Representative images of fluid accumulation in the cecum; C: Quantifications of fluid accumulation in the intestine; D: Representative western blot for intestinal calcium-sensing receptor (CaSR); E: Quantification of intestinal CaSR western blot. Mice were intragastrically gavaged with vehicle or cholera toxin at the indicated doses to induce diarrhea/intestinal fluid secretion. Three and half-hours later, animals were killed, intestines removed, and fluid and CaSR protein quantitated. The CaSR protein signals were normalized by heat shock protein 90 as an internal control to correct protein loading differences. Shown are means ± standard error. ^aP < 0.05, ^bP < 0.01 vs no cholera toxin control. The blue color noted in intestines was Evans Blue dye that was used to monitor intestinal motility (data not shown; will be reported separately). CTX: Cholera toxin; HSP90: Heat shock protein 90.

Table 1.

Intestinal fluid secretory responses to cholera toxin and R568 calcimimetic in calcium-sensing receptor wild type and mutant mouse intestine

Group	Intestinal fluid accumulation in mg fluid/mg intestine
	Wild type	villin Cre/Casrflox/flox	nestin Cre/Casrflox/flox
Control	0.20 ± 0.02 (11)	0.59 ± 0.13 (7)a	0.17 ± 0.02 (6)
R568 (50 mg/kg)	0.15 ± 0.09 (5)	0.61 ± 0.11 (5)	0.15 ± 0.11 (5)
CTX (0.5 mg/kg)	1.46 ± 0.15 (10)c	0.80 ± 0.03 (5)b	0.55 ± 0.14 (6)b
CTX (0.5 mg/kg) + R568 (50 mg/kg)	0.92 ± 0.16 (6)d	0.82 ± 0.09 (5)	0.95 ± 0.29 (5)

^a P < 0.05 vs wild type.

^b P < 0.05 vs control.

^c P < 0.01 vs control.

^d P < 0.05 vs cholera toxin alone.

Data are means ± standard error of means (n). CTX: Cholera toxin.

Many conditions like carcinogenesis reduce CaSR expression in the intestine[38]. To assess if this occurred to CTX-treated intestines, we examined CaSR protein expression by western blots (Figure 1). Although CTX caused diarrhea, the toxin did not alter intestinal CaSR expression. The CaSR/HSP90 protein signal ratios were control 0.50 ± 0.02 (5) vs CTX 0.53 ± 0.03 (5), P > 0.05.

R568 reverses CTX-induced diarrhea

Having known that CaSR protein expression was unaltered, we then studied CaSR function by assessing the ability of the calcimimetic R568 to reverse CTX-induced diarrhea in vivo (Figure 2). For this, the EC₅₀ dose 0.5 mg/kg of CTX was i.g. gavaged to induce moderate diarrhea, while different doses of R568 were administered i.p. Three and half hours later, animals were sacrificed, intestines were removed, and intestinal fluid was measured (Figure 2A). Indeed, CTX induced diarrhea (Figure 2B). When R568 was applied to the CTX-induced diseased intestine, it ameliorated diarrhea and reduced CTX-induced fluid accumulation (Figure 2B) in a dose-dependent manner. Fluid accumulation was reduced by approximately 50% when the near maximal effective doses of 30-50 mg/kg of R568 were applied (Figure 2C) (ANOVA test; P < 0.05). In non-CTX vehicle gavaged mice, R568 generated no or only minimal inhibitory effects (Figure 2C) (ANOVA test; P > 0.05). These results indicate that CaSR function remains unaltered in diseased intestines, consistent with the in vitro findings[13,15].

Figure 2.

Calcimimetic R568 reverses cholera toxin-induced diarrhea in wild type but not in intestine-specific calcium-sensing receptor knockouts. A: Experimental protocol; B: Representative images of R568 effect on fluid accumulation in the intestine of wild type mice; C: Summary of fluid accumulation in the intestine of wild type mice; D: Summary of fluid accumulation in the intestine of ^villinCre/Casr^flox/flox mice; E: Summary of fluid accumulation in the intestine of ^nestinCre/Casr^flox/flox mice. Mice were intragastrically gavaged with cholera toxin or vehicle while receiving R568 or vehicle intraperitoneally. Three and half-hours later, animals were killed, intestines removed, and fluid quantitated. Shown are means ± standard errors. ^aP < 0.05, ^bP < 0.01 vs without R568. CTX: Cholera toxin.

R568 reverses CTX-induced diarrhea via intestinal CaSR

To show that intestinal CaSR was indeed targeted and was not simply due to a non-specific off-target action, additional studies on intestinal tissue-specific CaSR knockout mice (i.e., ^villinCre/Casr^flox/flox and ^nestinCre/Casr^flox/flox) were performed and effects compared (Table 1, Figure 2D and E). Under non-CTX vehicle-stimulated basal conditions, intestinal fluid accumulation was increased in ^villinCre/Casr^flox/flox mice (0.59 ± 0.13 mg/mg intestine, P < 0.05 vs wild type mice) (Table 1), and was unchanged in ^nestinCre/Casr^flox/flox mice (0.17 ± 0.02 mg/mg intestine, P > 0.05 vs wild type mice) (Table 1). Addition of CTX (0.5 mg/kg) caused diarrhea, as evidenced by significantly increased intestinal fluid accumulation of these mice (Table 1), although the diarrhea was less severe in knockouts than in wild type (Table 1) due to activation of compensatory mechanisms. Importantly, R568 administration at all tested concentrations did not inhibit CTX-induced diarrhea in neither ^villinCre/Casr^flox/flox mice (ANOVA test; P > 0.05) (Figure 2D) nor ^nestinCre/Casr^flox/flox mice (ANOVA test; P > 0.05) (Figure 2E), confirming that the anti-diarrheic action was indeed exerted largely, if not exclusively, via CaSR in the intestinal tissues. R568 alone had no effect in neither ^villinCre/Casr^flox/flox mice (ANOVA test; P > 0.05) (Figure 2D) nor ^nestinCre/Casr^flox/flox mice (ANOVA test; P > 0.05) (Figure 2E) despite the presence of diarrhea in ^villinCre/Casr^flox/flox mice, further confirming that the CaSR is required for the calcimimetic to exert its anti-diarrheic action.

Effects of calcium

After performing the proof-of-concept studies using the calcimimetic R568 and verifying the functionality of intestinal CaSR, we tested whether targeting CaSR with calcium, an inexpensive widely available child-friendly mineral, was an anti-diarrheal in vivo. We added calcium to ORS and investigated whether it helped reduce the severity of diarrhea and enhance the rate of rehydration by ORS. In these experiments, animals were first i.g. gavaged with CTX or vehicle. Ninety minutes later, they were allowed to drink ORS with calcium or ORS alone, and development and progression of diarrhea was monitored both biochemically through changes in fecal Cl^- content and clinically by assessing changes in stool consistency and diarrhea-associated body weight loss (Figure 3A).

Figure 3.

Adding calcium to oral rehydration solution rescues cholera toxin-induced intestinal Cl^- loss and stool consistency, and promotes the rate of rehydration. A: Experimental protocol; B: Changes in fecal Cl^-; C: Changes in stool consistency score; D: Changes in % initial weight. At day 0, all animals were intragastrically gavaged with 20 μg/mouse of cholera toxin (CTX) to induce diarrhea. Ninety minutes later, they were allowed to drink oral rehydration solution (ORS), or ORS supplemented with 5 mmol/L calcium (ORS + Ca). Changes in fecal Cl^- (B), stool consistency score (C) and % initial weight (D) were monitored. Shown are means ± standard errors. n = 5-6 for each data point. No significant differences between groups were noted in initial body weights (in grams): Control:ORS vs ORS + Ca: 19.1 ± 0.6 vs 19.1 ± 0.6; CTX:ORS vs ORS + Ca: 19.9 ± 0.6 vs 19.5 ± 0.4. ^aP < 0.05, ^bP < 0.01 vs no cholera toxin controls; ^cP < 0.05 vs oral rehydration solution control. ORS: Oral rehydration solution; CTX: Cholera toxin.

Adding calcium to ORS reduces CTX-induced Cl^- losses from the intestine

In secretory diarrhea, active Cl^- secretion and decreased Cl^- absorption is the primary driving force for water moving from the blood to the intestinal lumen[39]. Thus, to assess whether calcium supplemented ORS (ORS + Ca) is better than ORS alone in reducing intestinal Cl^- loss from diarrhea, we first measured and compared changes in fecal Cl^- concentration (Cl^-). Figure 3B shows the changes in fecal Cl^- at day 1, day 4, and day 6 post-CTX gavage. Day 1 represents the acute stage of diarrhea, day 4 the recovery stage, and day 6 post-recovery. Consistent with enterotoxin-induced intestinal Cl^- loss, mice in both groups displayed a significantly higher mean fecal Cl^- upon CTX exposure (P < 0.01, day 1 post CTX vs day 1 Control). However, compared to the high fecal Cl^- in CTX:ORS-treated mice, a lower fecal Cl^- was noted in mice receiving CTX:(ORS + Ca) treatment (ANOVA test P < 0.05; Student’s t test P values at day 1, 4 and 6 = 0.56, 0.07 and 0.08 vs respective non-Ca controls). Moreover, relative to mice on CTX:ORS treatment, mice on CTX:(ORS + Ca) recovered from diarrhea-associated Cl^- losses significantly faster. Thus, while the CTX:ORS group fecal Cl^- losses had remained significantly elevated above baseline until day 6 post-CTX gavage, in CTX:(ORS + Ca) group, a close to normal fecal Cl^- had been observed at day 4 post-CTX treatment (Figure 3B). Calcium had no or minimal effects on non-CTX vehicle-treated mice (one-way ANOVA test; P > 0.05). These results suggest that ORS + Ca is better than ORS alone in reducing diarrhea-associated intestinal Cl^- losses.

Adding calcium to ORS reduces severity and duration of CTX-induced diarrhea

Reducing intestinal Cl^- loss suggests the possibility of reducing diarrhea and dehydration. Thus, we compared the onset, severity and recovery of diarrhea/dehydration induced by CTX in ORS + Ca vs ORS groups. First comparison was made regarding the onset of diarrhea (i.e., the time from CTX gavage to the appearance of the first diarrheic stool). Since it would take some time for calcium to produce a clinically visible anti-diarrheal action, calcium may or may not influence the onset of diarrhea. Before CTX gavage, all mice displayed normal solid stool. Following CTX gavage, mice receiving ORS had the first diarrheic stool at 4.5 ± 1.7 h, whereas mice receiving ORS + Ca developed diarrhea at 4.3 ± 1.8 h. No statistically significant difference was noted (P = 0.69).

We then compared the changes in stool consistency over time. Similarly, adding calcium reduced the stool consistency score in CTX-treated (ANOVA test; P < 0.05) but not in the non-CTX control (ANOVA test; P > 0.05). The result is summarized in Figure 3C. Specifically, in ORS group, CTX significantly increased stool consistency scores on day 1, day 2 and day 3 but not on day 4 compared to the non-CTX control, whereas in ORS + Ca group, CTX significantly increased stool consistency scores only on day 1 and day 2 but not on day 3 and day 4. Thus, while the ORS group stool consistency score remained significantly elevated above baseline until day 4 post-CTX gavage, in ORS + Ca group, a normal stool consistency score had been observed 1 d earlier at day 3 post-CTX treatment. These results suggest that ORS + Ca is better than ORS alone in reducing diarrhea.

Considering that the stool consistency scoring is only semi-quantitative and has large performance-dependent variations, we compared body weight changes before and after disease induction, a quantitative way of measuring diarrhea severity and degree of dehydration[32]. We chose to monitor body weight instead of monitoring 24-h stool volume because we had technical difficulties in accurately collecting stool and quantifying 24-h stool volume. Figure 3D shows body weight changes over time in mice in ORS + Ca group vs ORS only group along with their non-CTX controls. In response to CTX challenge, mice on both groups lost significant weight, particularly in day 1 and day 2. However, mice receiving ORS + Ca lost significantly less weight and recovered significantly sooner than mice receiving ORS only (ANOVA test; P < 0.01). Thus, while mice in the ORS group continued to lose weight to a statistically significant degree until after day 4 post-CTX, mice in ORS + Ca group had achieved a close to normal body weight at day 3 pos-CTX treatment (Figure 3D). The estimated time at which mice returned to their initial weight was 3.5 d in Ca-ORS group and 4.5 d in ORS only group, which is 22% faster in ORS + Ca group. These results suggest that adding calcium to ORS reduces the severity of dehydration, hastens its recovery, and accelerates the rate of rehydration by ORS.

DISCUSSION

This first in vivo study proves that targeting intestinal CaSR with calcium or calcimimetic is efficacious in reducing CTX-evoked secretory diarrhea and that this occurs through receptor-mediated reduction of both the neurally (i.e., Nestin-expressing enteric neuron) and non-neuronally (i.e., Villin-expressing epithelial cell) mediated Cl^- secretory responses. A schematic diagram illustrating how CTX induces and calcium/calcimimetic inhibits these two Cl^- secretory responses is depicted in Figure 4.

Figure 4.

Diagram illustrates how cholera toxin stimulates and calcium/calcimimetic inhibits the dual pathways of Cl^- secretion resulting in diarrhea. Cholera toxin (CTX) via G_s α-subunit stimulates transepithelial Cl^- secretion both neurally through Nestin-expressing enteric neurons releasing neurotransmitters and non-neuronally through direct action on Villin-expressing epithelial cells. The outcome is stimulating both Cl^- entry from blood side into intestinal epithelial cell and exit from epithelial cell into the intestinal lumen causing secretory diarrhea. On the other hand, Ca²⁺/calcimimetic via calcium-sensing receptor (CaSR) inhibits both actions of CTX via direct epithelial action and indirectly via enteric neuron. The involvement of Nestin-expressing enteric neurons and Villin-expressing epithelial cells is evidenced in the two tissue-specific knockout mice whose Cl^- secretory responses to CTX and CaSR stimulation are compromised.

We showed that CTX induced secretory diarrhea in mice as previously reported[19-22]. This was evidenced by increased fecal Cl^- and water content/stool consistency and weight loss following CTX induction. Importantly, although it altered intestinal fluid balance and caused diarrhea, CTX did not seem to alter CaSR content or function. Accordingly, when applied to diseased intestines, calcium and calcimimetic were each able to ameliorate diarrhea. Intestinal CaSR involvement is further supported by gene knockout experiments in which the anti-diarrheal activity of CaSR agonists observed in wild type mice was not noted in knockouts. Neither the ^villinCre/Casr^flox/flox mice that lack epithelial CaSR nor the ^nestinCre/Casr^flox/flox mice that lack neuronal CaSR experienced amelioration of diarrhea with CaSR agonists.

Interestingly, while both CaSR knockouts responded to CTX stimulation, their responses were less prominent than their wild types. The reason is unknown and is related to the downregulation of NKCC1 and CFTR in these animals[32]. NKCC1 and CFTR are two ion transporters required for the intestine to generate an effective diarrheal response to secretagogues[40,41].

Additionally, differences in the phenotype of two intestinal CaSR knockouts under basal conditions are noted. While ^villinCre/Casr^flox/flox mice developed spontaneous diarrhea, as evidenced by mild but significant increased fluid accumulation in unstimulated intestines, ^nestinCre/Casr^flox/flox mice did not, as there was no increase in fluid accumulation in unstimulated intestines (Table 1). The reason is unknown but may be related to the fasting condition used and differences in roles and functions these epithelial and neuronal CaSR receptors play in intestinal function. The primary function of the gastrointestinal (GI) tract is to digest food and absorb nutrients. To aid digestion, the GI tract secretes a large amount of fluid to mix the food components and lubricate the luminal surface. It is estimated that following the ingestion of a meal, intestinal secretion can be increased eightfold[42]. Upon completion of digestion and extraction of nutrients, intestinal secretion stops. While studies suggest that mechanical sensors in the ENS have a significant role in triggering the meal-evoked secretion[6], there is evidence that chemical sensors (e.g., CaSR) on the epithelium and enteric neurons have a key role in terminating this process. The latter do so through their ability to sense nutrients released during digestion[25] (also, a recent review by Tang et al[10]). Consistent with active regulation of intestinal secretion by CaSR, under the no-food-no-nutrient fasting condition used in the present study, neuronal CaSR would have been silent and, as a result, no intestinal phenotype would be expected in ^nestinCre/Casr^flox/flox mice (Table 1).

The finding of spontaneous diarrhea in ^villinCre/Casr^flox/flox mice is notable (Table 1). This indicates that unlike neuronal CaSR, epithelial CaSR does remain active, at least to some degree, under a no-food-no-nutrient fasting condition. This is not surprising given the multiple roles and functions that CaSR plays in GI biology[43]. In addition to its established function as a nutrient sensor regulating fluid secretion and absorption during food digestion, epithelial CaSR is a fundamental mechanism for sensing and regulating the ionic and nutrient compositions of extracellular milieu surrounding the epithelium of the entire GI tract[10]. Thus, at basal no-food no-nutrient fasting state, this epithelial CaSR may perform other tasks, for example, monitoring the Ca²⁺ surrounding the epithelium.

According to the present model of intestinal Ca²⁺ transport[44], the Ca²⁺ ion cycles between the leaking crypt, which secretes Ca²⁺ via a passive paracellular pathway, and the electrically tight villous/surface epithelium, which absorbs back Ca²⁺ via an active transcellular transport mechanism. Interestingly, under basal conditions, fluid also cycles in a similar fashion between the crypt, which secretes, and the villous/surface epithelium, which absorbs[45]. The purpose of this fluid cycling is to lubricate the luminal surface to prevent the crypt lumen from obstructing and to defend the crypt from invasion by lumen bacteria. It is likely that CaSR located on enterocyte apical and basolateral membranes constitutively sense Ca²⁺, thereby monitoring and controlling these processes.

CONCLUSION

The most notable observation of the present study is that calcium and calcimimetic both significantly ameliorated CTX-induced secretory diarrhea. The latter has important therapeutic value. Treatment of acute secretory diarrheas remains a global challenge. Despite advances in diarrhea research, few advancements have been made in the realm of diarrhea therapeutics, and ORS therapy has remained the standard of care even though it does not stop the loss of intestinal fluid and ions caused by pathogens. There is no cost-effective therapeutic for diarrhea. This study suggests that adding calcium to ORS or using calcimimetic to activate intestinal CaSR might represent a novel approach for treating secretory diarrheal diseases. Limitations of this study include: (1) The present study was an animal but not human study; (2) No data on oral calcimimetic was obtained; and (3) Neither local nor systemic adverse effects were documented, despite the fact that some animals in study protocol 1 appeared to be sick, particularly at day 2 following the exposure of disease-causing CTX. Better designed animal studies and randomized clinical trials in humans are warranted.

ARTICLE HIGHLIGHTS

Research background

Treatment of diarrhea such as cholera remains a global challenge. Cholera toxin (CTX) produces diarrhea through direct epithelial action and indirectly by activating the enteric nervous system. Calcium-sensing receptor (CaSR) is present in both tissues and, when activated, inhibits both actions. The latter has been well documented in vitro but not in vivo. Thus, the present study tested whether activating intestinal epithelial or neuronal CaSR inhibits diarrhea in vivo.

Research motivation

Acute infectious diarrhea remains among the top causes of morbidity and death in the world. Most of the morbidity and mortality is not due to infection but dehydration. Accordingly, how to effectively reduce the fluid loss from acute diarrhea offers a major opportunity for improving global health.

Research objectives

The objective of the present study was to determine whether CaSR agonists ameliorate secretory diarrhea evoked by CTX in wild type mice, epithelial-specific CaSR knockout mice (^villinCre/Casr^flox/flox) and neuronal-specific CaSR knockout mice (^nestinCre/Casr^flox/flox).

Research methods

To realize the objectives, CTX was administered orally to C57BL/6 mice to induce secretory diarrhea while calcium and calcimimetic R568 were employed to activate CaSR. To maximize their local intestinal actions, calcium was administered luminally via oral rehydration solution (ORS) whereas R568 was applied serosally using an intraperitoneal route. To verify that their actions resulted from the intestinal epithelium and enteric neurons, effects were also examined on two Cre-lox intestine-specific CaSR knockouts. Diarrhea outcome was measured biochemically by monitoring changes in fecal Cl^- or clinically by assessing stool consistency and weight loss.

Research results

CTX induced secretory diarrhea, as evidenced by increases in fecal Cl^-, stool consistency, and weight loss following CTX exposure. Calcium and R568 each ameliorated CTX-induced secretory diarrhea in wild type mice but not in either knockout mouse model.

Research conclusions

Based on the present study, we propose that activating intestinal epithelial or neuronal CaSR can inhibit secretory diarrhea in vivo. Adding calcium to ORS or using calcimimetic to activate intestinal CaSR might represent a novel approach for treating secretory diarrheal diseases in humans.

Research perspectives

Future research should be directed to conduct randomized clinical trials utilizing calcium or calcimimetics to treat cholera and other secretory diarrheal diseases in humans.

Data sharing statement

No additional data are available.